BioSpace News Archive

NDA supported by positive interim analysis results from the Phase 3 REGENERATE study demonstrating OCA’s improvement of liver fibrosis without worsening of NASH

Fulgent Genetics, Inc. announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Vice President of Commercial Operations Brandon Perthuis are scheduled to participate in the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at the Lotte New York Palace Hotel in New York, New York.

Surface Oncology announced it has secured a debt financing facility for up to $25 million from K2 HealthVentures, a healthcare-focused specialty finance company.

IMVT-1401, a fully human anti-FcRn antibody designed to be administered via subcutaneous injection, is the only anti-FcRn antibody known to be in clinical development for the treatment of GO

La Jolla Pharmaceutical Company, a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, has left the Company to pursue other interests.

Dr. Singh is renowned for her expertise in molecular science, clinical management and national health policy

La Jolla Pharmaceutical Company, a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, announced that it will reassess continued development of LJPC-401 based on recent mixed clinical results.

Azzur Welcomes Tita Tavares as Director of Its New Office in Washington, D.C.

First and only FDA-approved sickle hemoglobin polymerization inhibitor, a new class of therapy

Agreement with speciality chemical company, Croda International, to design and manufacture a new active skincare ingredient based on SkinBiotix™ technology and investigate specific cosmetic ingredient applications to target.